These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18248272)

  • 1. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
    Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.
    Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J
    Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs associated with ventricular assist device use in children.
    Mahle WT; Ianucci G; Vincent RN; Kanter KR
    Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable ventricular assist devices: is it time to introduce them in Canada?
    McGregor M
    Can J Cardiol; 2000 May; 16(5):629-40. PubMed ID: 10833542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
    Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
    Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular assist devices.
    Birks EJ
    Heart; 2010 Jan; 96(1):63-71. PubMed ID: 19617213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(3):1-60. PubMed ID: 27026798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac recovery during mechanical assist device support.
    Maybaum S; Kamalakannan G; Murthy S
    Semin Thorac Cardiovasc Surg; 2008; 20(3):234-46. PubMed ID: 19038734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart transplant and left ventricular assist device costs.
    Digiorgi PL; Reel MS; Thornton B; Burton E; Naka Y; Oz MC
    J Heart Lung Transplant; 2005 Feb; 24(2):200-4. PubMed ID: 15701438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program.
    Clarke A; Pulikottil-Jacob R; Connock M; Suri G; Kandala NB; Maheswaran H; Banner NR; Sutcliffe P
    Int J Cardiol; 2014 Feb; 171(3):338-45. PubMed ID: 24424339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic aspects of implementation of the mechanical heart, "HeartMate"].
    Kolbye A; Sander Jensen KM; Aldershvile J; Hansen PB; Kjersem AM; Nielsen KS; Olsen PS; Rasmussen B; Vogelsang G
    Ugeskr Laeger; 2000 Jun; 162(26):3722-5. PubMed ID: 10925632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pediatric heart transplantation.
    Dayton JD; Kanter KR; Vincent RN; Mahle WT
    J Heart Lung Transplant; 2006 Apr; 25(4):409-15. PubMed ID: 16563970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving costs of long-term left ventricular assist device implantation.
    Gelijns AC; Richards AF; Williams DL; Oz MC; Oliveira J; Moskowitz AJ
    Ann Thorac Surg; 1997 Nov; 64(5):1312-9. PubMed ID: 9386696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients.
    Kamdar F; Boyle A; Liao K; Colvin-adams M; Joyce L; John R
    J Heart Lung Transplant; 2009 Apr; 28(4):352-9. PubMed ID: 19332262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of continuous-flow left ventricular assist devices.
    Neyt M; Van den Bruel A; Smit Y; De Jonge N; Erasmus M; Van Dijk D; Vlayen J
    Int J Technol Assess Health Care; 2013 Jul; 29(3):254-60. PubMed ID: 23763844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of ventricular assist device therapy as a bridge to transplantation compared with nonbridged cardiac recipients.
    Alba AC; Alba LF; Delgado DH; Rao V; Ross HJ; Goeree R
    Circulation; 2013 Jun; 127(24):2424-35. PubMed ID: 23697907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic relief: left ventricular assist devices versus resynchronization therapy.
    Delgado RM; Radovancevic B
    Heart Fail Clin; 2007 Jul; 3(3):259-65. PubMed ID: 17723934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.